CN Patent

CN101730699A — 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物

Assigned to Bristol Myers Squibb Co · Expires 2010-06-09 · 16y expired

What this patent protects

具有式(I)化合物及其对映异构体、非对映异构体和药用盐可用作激酶调节剂，包括Btk调节，其中R 1 、R 2 、R 4 、Q、Y、A和D如本申请中所定义。

USPTO Abstract

具有式(I)化合物及其对映异构体、非对映异构体和药用盐可用作激酶调节剂，包括Btk调节，其中R 1 、R 2 、R 4 、Q、Y、A和D如本申请中所定义。

Drugs covered by this patent

Wayrilz (RILZABRUTINIB) · Genzyme Corp

Patent Metadata

Patent number: CN101730699A
Jurisdiction: CN
Classification: —
Expires: 2010-06-09
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.